Hepatitis C cure, sofosbuvir, turns 5 years old: The vast majority of people still have not been treated

Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits. 6 December 2018, Paris, (...) More
Global Declaration to Eliminate Hepatitis C in People Who Use Drugs: A call for political leaders to take action

Sign the pledge! If elimination by 2030 is to be achieved, the global community needs to act immediately. More
Hepatitis C among People who use drugs 61th CND Side Event (March 2018)

On March 16th, during the 61th Session of the Commission on Narcotic Drugs (CND) held in Vienna (Austria), a side event untitled “Hepatits C among people who use drugs – the global state and (...) More
Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics Report of the World Community Advisory Board on HCV Generics and Diagnostics 18-20 July 2017, Bangkok, Thailand

In July 2017, 37 treatment activists from 17 countries—including 14 low- and middle-income countries (LMICs)—met with representatives from three generics and three diagnostics companies. This (...) More
WORLD HEPATITIS SUMMIT: NO ELIMINATION WITHOUT DECRIMINALIZATION! 18 civil society organisations call world leaders to promote harm reduction and decriminalise drug use

São Paulo, Brazil – November 2nd 2017. At the occasion of the World Hepatitis Summit, a large coalition of patients, clinicians, social workers, representatives of the drug using community, (...) More
Dying at these prices: Generic HCV cure denied mapCrowd report #2

To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org. More

Recent publications

Updated Hepatitis C Treatment Guidelines

Geneva - July 2018
The World Health Organization released the updated Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. They follow and update the screening and care section of the WHO Guidelines for the screening, care and treatment of (...) More
8 November 2018
Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV

This Training Manual was designed and updated in February 2018 by Treatment Action Group (TAG), an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.
The purpose (...) More
22 February 2018
Tackling hepatitis C – Pakistan’s road to success

The annual World Hepatitis Summit in São Paulo, Brazil took place in November 2017 to take stock of the World Health Organization’s global health sector strategy on viral hepatitis 2016–2020. The international community called for immediate, innovative, and coherent policy interventions, backed by evidence-based research. In 2015, the viral hepatitis pandemic (largely hepatitis B and C) caused an estimated 1.4 million deaths, however, the attention and response by donors and policy-makers has been woefully inadequate. An Editorial in The Lancet draws attention to this inaction, and new data indicate that action has been fragmented and insufficient. Only 82 countries, including Pakistan, have adopted strategies to eliminate viral hepatitis by 2030. More
13 March 2018
Trainings Hepatitis C and harm reduction for people who use drugs

Between March and October 2016, Doctors of the World/Médecins du Monde (MdM) organized a series of trainings on Hepatitis C intended for its Harm Reduction international teams and partners with a focus on people who use drugs. More
12 January 2017
Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition Paris, October 5th 2016

European Patent Office (EPO) has taken its decision following Doctors of the World - Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
MdM has filled an opposition on the patent granted to Gilead Sciences for (...) More
5 October 2016